You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GD2 CAR T cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T Infusion)

Not yet recruiting
  • Lung Cancer
  • +2 more
  • iC9.GD2.CAR.IL-15 T Infusion
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Nov 16, 2022

Solid Tumor Trial in Shenzhen (bi-4SCAR GD2/PSMA T cells)

Recruiting
  • Solid Tumor
  • bi-4SCAR GD2/PSMA T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Cancer Disease Trial in Shenzhen (bi-4SCAR GD2/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR GD2/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Malignant Disease Trial in Shenzhen (bi-4SCAR GD2/CD56 T cells)

Recruiting
  • Malignant Disease
  • bi-4SCAR GD2/CD56 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma Trial in Bethesda, Seattle, Madison (Cyclophosphamide,

Recruiting
  • Recurrent Neuroblastoma
  • +3 more
  • Palo Alto, California
  • +3 more
Jan 25, 2023

Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Neuroblastoma
  • GINAKIT Cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Jan 18, 2023

Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor Trial in Houston ((C7R)-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Diffuse Intrinsic Pontine Glioma
  • +3 more
  • (C7R)-GD2.CART cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Feb 7, 2022

Diffuse Midline Glioma, H3 K27M-Mutant Trial (GD2 CAR T cells)

Not yet recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • GD2 CAR T cells
  • (no location specified)
Sep 15, 2022

Neuroblastoma Trial (GD2 CAR T cells)

Not yet recruiting
  • Neuroblastoma
  • GD2 CAR T cells
  • (no location specified)
Aug 5, 2023

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Osteosarcoma, Neuroblastoma Trial in Houston (genetic, biological, drug)

Active, not recruiting
  • Osteosarcoma
  • Neuroblastoma
  • GD2 T cells
  • +3 more
  • Houston, Texas
  • +1 more
Apr 16, 2021

Neuroblastoma, Osteosarcoma Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Neuroblastoma
  • Osteosarcoma
  • iC9.GD2.CAR.IL-15 T-cells
  • +2 more
  • Atlanta, Georgia
  • +1 more
Jan 4, 2023

Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors Trial in Roma (GD2-CART01)

Recruiting
  • Neuroblastoma
  • +5 more
  • GD2-CART01
  • Roma, Italy
    Ospedale Pediatrico Bambino Gesù
Mar 9, 2022

Glioma of Spinal Cord, Glioma of Brainstem Trial in Stanford (GD2 CAR T cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Glioma of Spinal Cord
  • Glioma of Brainstem
  • GD2 CAR T cells
  • +2 more
  • Stanford, California
    Lucile Packard Children's Hospital (LPCH)
Jun 22, 2022

Brain Tumor, Pediatric, Medulloblastoma, Childhood, Embryonal Tumor Trial (GD2-CART01 (iC9-GD2-CAR T-cells))

Not yet recruiting
  • Brain Tumor, Pediatric
  • +6 more
  • GD2-CART01 (iC9-GD2-CAR T-cells)
  • (no location specified)
Mar 18, 2022

Neuroblastoma Trial in Houston (iC9-GD2 T Cells - frozen, iC9-GD2 T Cells - fresh, Cytoxan)

Active, not recruiting
  • Neuroblastoma
  • iC9-GD2 T Cells - frozen
  • +5 more
  • Houston, Texas
  • +1 more
Jan 4, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Glioma of Brain, CAR-T Cell Immunotherapy Trial (GD2 CAR-T immunotherapy)

Withdrawn
  • Glioma of Brain
  • CAR-T Cell Immunotherapy
  • GD2 CAR-T immunotherapy
  • (no location specified)
Jul 14, 2020

GD2 Positive Glioma, CAR-T Cell Immunotherapy Trial in Guangzhou (CAR-T cell immunotherapy)

Withdrawn
  • GD2 Positive Glioma
  • CAR-T Cell Immunotherapy
  • CAR-T cell immunotherapy
  • Guangzhou, Guangdong, China
    Central laboratory in Fuda cancer hospital
Jul 14, 2020

Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)

Not yet recruiting
  • Neuroendocrine Tumor (NET)
  • Colorectal Cancer (CRC)
  • CHM-2101 CAR-T cells
  • (no location specified)
Sep 20, 2023

Advanced Solid Tumor Trial in Shanghai (B4T2-001 autologous CAR-T)

Recruiting
  • Advanced Solid Tumor
  • B4T2-001 autologous CAR-T
  • Shanghai, China/Shanghai, China
  • +1 more
Oct 3, 2023

Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

Not yet recruiting
  • Solid Tumor
  • Intravenous infusion anti-HER2-CAR-T cell
  • Shenyang, Liaoning, China
    Phase I Clinical Trials Center Of The First Hospital of China Me
Oct 30, 2023

Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)

Not yet recruiting
  • Large B-cell Lymphoma
  • B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2023

Relapsed/Refractory Multiple Myeloma Trial in Philadelphia (Cevostamab)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Philadelphia, Pennsylvania
    Hospital of the University of Pennsylvania
Apr 7, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023